Latest News

Best disease, also known as vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and potentially blindness.

Kenneth C. Fan, MD, discusses promising visual improvements from MCO-010 therapy for Stargardt disease at AAO 2025, highlighting future treatment potential.

Anat Loewenstein, MD, discusses the transformative impact of home OCT and AI on monitoring retinal diseases at AAO 2025.

In the study, authors investigated the natural history of GA lesion incidence rates and analyzed potential risk factors for faster incidence of GA lesions.

OPGx-LCA5 is designed to address a form of Leber congenital amaurosis that results from biallelic mutations in the LCA5 gene, which encodes the lebercilin protein, the investigators explained.

New five-year data reveals SYFOVRE significantly delays geographic atrophy progression, enhancing understanding of age-related macular degeneration treatment.

Research on aflibercept 8 mg reveals promising real-world outcomes for treating wet AMD and diabetic macular edema, enhancing vision and safety.

PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform treatment and improve children's vision.

Stephen Tsang, MD, PhD, reviews promising optogenetic therapy results for retinitis pigmentosa and Stargardt disease, enhancing vision and mobility for patients.

Ophthalmologists weigh in on how the extended-duration therapy may reduce treatment burden for patients with wet age-related macular degeneration.

Sharon Fekrat, MD, FACS, FASRS, shares insights on the retinal manifestations of antipsychotic medications.

The EXTEND study is a 5-year follow-up of participants who received a single intravitreal injection of MCO-010 in a previously conducted phase 1/2a trial.

The trial is evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).

The funding will support the completion of the clinical PoC of its AAVB-039 CELESTE study and the completion of the STELLA natural history study.

Under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases in Japan, China, Australia, and other Asia-Pacific markets.

Catch up on this week's highlights in retina.

The trial will be evaluating AXPAXLI dosed every 6 months vs aflibercept (2 mg) dosed every 8 weeks in treatment-naive patients with wet AMD.

A mutation-agnostic gene therapy approach offers new possibilities for patients, especially those with inherited retinal diseases.

NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy of a single intravitreal injection of SPVN20 over 6 months.

This acquisition will include Adverum’s lead candidate, Ixo-vec, a gene therapy treatment for wet AMD.

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.

A study reveals that lesion characteristics in geographic atrophy significantly influence growth rates, highlighting the need for targeted treatment strategies.

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr Feistmann in an overview of office-based surgery, with actionable advice for retina specialists considering this approach.

Catch up on this week's highlights in retina.

Topcon Healthcare enhances its AI capabilities by acquiring Toku, Inc, aiming to revolutionize eye care with advanced predictive health insights.

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

New research highlights iron dysregulation's role in dry AMD, suggesting transferrin as a promising treatment to slow disease progression.

Retina specialists share their perspectives on evolving anti-VEGF therapy, pipeline treatments, and strategies to enhance patient outcomes.

Xelafaslatide (formerly ONL1204) is a small-molecule Fas inhibitor designed to protect key retinal cells from cell death that occurs across multiple retinal diseases and conditions such as geographic atrophy.

A new study reveals a promising drug reduces vision loss in Stargardt disease, showing significant safety and efficacy over 2 years.

Innovative retinal therapies are advancing through FDA trials, promising breakthroughs in treating various retinal diseases.